Exelixis
EXEL
#1807
Rank
C$15.17 B
Marketcap
C$56.60
Share price
0.17%
Change (1 day)
5.94%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): C$3.30

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$3.27. In 2023 the company made an earnings per share (EPS) of C$0.90 an increase over its 2022 EPS that were of C$0.78.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$3.30
2023C$0.9014.61%
2022C$0.78-22.97%
2021C$1.02100%
2020C$0.51-65.09%
2019C$1.45-53.91%
2018C$3.16333.96%
2017C$0.73-260.61%
2016C-$0.45-58.75%
2015C-$1.10-42.45%
2014C-$1.915.3%
2013C-$1.81

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$15.28 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.87-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$19.67 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$2.83-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$10.03 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$4.08 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$5.17 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$5.04-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.15-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA